Home  Guidelines for Reviewers About the Journal News Editorial Board Aims & Scope Subscription Contact us Announcement Peer Review Policy Content
Early Edition  //  Current Issue  //  Archives  //  Most Read

General Chemistry

Special Issue: Bioanalysis

• Perspective • Previous Articles     Next Articles

Ultrasensitive in-vitro Detection Assay for Non-invasive Alzheimer’s Disease Diagnosis

See-Lok Ho,a Hei-Nga Chan,a Hung-Wing Li,*,b and Man-Shing Wong*,b   

  1. a MIND and Tech, Ltd., Fo Tan, Hong Kong, China
    b Hong Kong Baptist University, Department of Chemistry, Kowloon Tong, Hong Kong, China
  • Received:2019-12-12 Revised:2019-12-13 Online:2020-12-20
  • Contact: hwli@hkbu.edu.hk (H. W. L.), mswong@hkbu.edu.hk (M. S. W.)
  • Supported by:

Abstract: Alzheimer’s disease (AD) is the most prevalent cause of dementia. According to the Alzheimer’s Disease Association, there are over 37 million patients currently suffering from AD. To date, there is still no standard method for accurate AD diagnosis. Detection of biomarkers has become a new trend for disease diagnosis as research has shown that alternation of the expression profile of biomarkers occurs over 10 years before the development of any symptoms. Recently, there is a considerable development in the field of ultrasensitive detection assay for AD diagnosis. This perspective gives an updated review of the current state of development on body fluid-based detection assay for non-invasive AD diagnosis.


Key words: Alzheimer’s disease, biomarkers, non-invasive, diagnosis, immunoassay

Copyright © General Chemistry, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States